Ravulizumab
- Generic Name
- Ravulizumab
- Brand Names
- Ultomiris
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1803171-55-2
- Unique Ingredient Identifier
- C3VX249T6L
- Background
Ravulizumab is a potent and selective complement 5 (C5) inhibitor. It is a humanized monoclonal IgG2/4 kappa antibody produced in Chinese hamster ovary (CHO) cells. Ravulizumab was engineered from eculizumab, another complement inhibitor, to increase the duration of action and reduce the frequency of drug administration. It works by blocking terminal complem...
- Indication
Ravulizumab is indicated for the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH).
...
- Associated Conditions
- Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis, Paroxysmal Nocturnal Haemoglobinuria (PNH), Thrombotic Microangiopathies
- Associated Therapies
- -
Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment
- Conditions
- Interventions
- First Posted Date
- 2020-09-22
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 97
- Registration Number
- NCT04558918
- Locations
- 🇺🇸
City Of Hope National Med Center City of Hope Medical Center, Duarte, California, United States
🇺🇸Augusta University Georgia Patient Treatment, Augusta, Georgia, United States
🇺🇸Univ Cali Irvine ALS Neuromuscular, Orange, California, United States
Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT04543591
- Locations
- 🇬🇧
Research Site, Wirral, United Kingdom
mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)
- First Posted Date
- 2020-05-15
- Last Posted Date
- 2020-05-18
- Target Recruit Count
- 1167
- Registration Number
- NCT04390464
- Locations
- 🇬🇧
Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom
Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab
- Conditions
- Interventions
- First Posted Date
- 2020-03-25
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04320602
- Locations
- 🇬🇧
Clinical Study Site, London, United Kingdom
🇬🇧Research Site, London, United Kingdom
An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD
- Conditions
- Interventions
- First Posted Date
- 2019-12-17
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT04201262
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
- Conditions
- Interventions
- First Posted Date
- 2018-11-21
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 139
- Registration Number
- NCT03748823
- Locations
- 🇹🇷
Research Site, Izmir, Turkey
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.